The healthcare conglomerate reported strong sales in the first quarter that were largely due to growth of its pharmaceutical business, but got an extra boost from the continued renewal of its consumer products portfolio.

FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.

In a conversation shortly before taking the helm at Johnson & Johnson, CEO Gorsky discusses deal strategies, emerging markets, his experience on both the device and pharma sides of the business, and opportunities for drug/device convergence.